PLAU and ovarian carcinoma: Several studies have demonstrated that LPA activates proteolytic enzymes, including urokinase plasminogen activator (uPA) [45–47], matrix metalloproteinases (MMPs) MMP-2 [48] and MMP-9 [49] and VEGF [50–52], to augment ovarian cancer invasion and metastasis.